SUSAN ALDEN: Open Payments
NPI 1629079280 · MILAN, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,099 in 94 payments from 26 companies in 2025. Trend: 2023 $1,083 · 2024 $2,218 · 2025 $2,099
Food & beverage: $2,099
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $423 |
| Vanda Pharmaceuticals Inc. | 13 | $363 |
| Alkermes, Inc. | 8 | $192 |
| Axsome Therapeutics, Inc. | 4 | $110 |
| Novo Nordisk Inc | 4 | $84 |
| E.R. Squibb & Sons, L.L.C. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
Products named: FANAPT, VRAYLAR, LYBALVI, Auvelity, REXULTI, COBENFY, AUSTEDO XR, CAPLYTA.
Industry payments across IL — which companies pay providers there.
